Nitric oxide has witnessed increased demand owing to its rise in use in the medical sector and during the Covid-19 pandemic.
Nitric oxide has witnessed increased demand owing to its rise in use in the medical sector and during the Covid-19 pandemic. When the inhaled nitric oxide is used through the nose or mouth, it relaxes the smooth muscles as well as widens the blood vessels in the lungs. In addition, the inhaled nitric oxide gas is used along with a ventilator or breathing machine during the treatment of newborns who suffer from pulmonary hypertension.
As per a report published by Allied Market Research, the global inhaled nitric oxide market is expected to garner $1.18 billion by 2027, registering a CAGR of 8.1% from 2020 to 2027. Surge in need from the healthcare sector and the rise in chronic diseases drive the growth of the market. Moreover, incidences of diseases in newborns including pulmonary hypertension and HRF has supplemented the market growth.
increase in the prevalence of respiratory treatment in neonates has resulted in increased use of inhaled nitric oxide therapy. Furthermore, increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF) increased the demand for the growth of the inhaled nitric oxide market
Download Sample Report at : https://www.alliedmarketresearch.com/request-sample/3020
Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. It has emerged as a treatment for hypoxemic respiratory failure in newly born infants that is associated with persistent high pulmonary vascular pressure and resultant right-to-left shunting of blood (persistent pulmonary hypertension of the newborn. For instance- each year around 2% of all live births and >33% of neonatal mortality occurs due to neonatal hypoxic respiratory failure (HRF).
Inhaled nitric oxide gas in Covid-19 treatment:
During the Covid-19 pandemic, several patients struggled to breathe on their own and some suffered from Covid-19-related hypoxemic respiratory. Thus, several researchers suggested the use of pre-intubation of nitric oxide gas to reduce patient mortality. Moreover, it may reduce the need for future intubation and other invasive ventilation. Several other researchers have suggested that there is a need for trial investigation to determine the efficacy of inhaled nitric oxide gas as a valid Covid-19 treatment.
Inhaled nitric oxide is currently approved for the treatment of persistent pulmonary hypertension of the newborn (PPHN) due to inhaled nitric oxide antibacterial and oxygenation properties inhaled nitric oxide is a targeted pulmonary vasodilator that improves clinical outcomes for newborn patients with persistent pulmonary hypertension of the newborn.
Inhaled nitric oxide in pediatric practice and cardiac surgery:
As mentioned above, nitric oxide gas plays a crucial role in human physiology. In the treatment of inflammation and neural transmission, inhaled nitric oxide gas is widely accepted. The use of nitric oxide gas for hypoxaemic respiratory failure has increased. Apart from this, inhaled nitric oxide gas has been used to treat cardiothoracic surgeries. As nitric oxide gas combines instantly with hemoglobin, it helps minimize postoperative complications and aids in maintaining systemic blood pressure.
Inhaled nitric oxide gas is used in the management of patients who have a history of cardiothoracic surgeries. In addition, inhaled nitric oxide is proven to be an ideal way to the management of cardiothoracic surgeries. Having said that, the inhaled nitric oxide gas is widely used in the healthcare sector owing to its ability to boost oxygenation in newborns and adults. As this therapy is widely approved by researchers, in the coming years, more opportunities would unlock, for which market players must be prepared.